Global Image-Guided Biopsy Market - 2022-2029

Global Image-Guided Biopsy Market - 2022-2029
Market Overview

Image-Guided Biopsy Market size was valued at US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of 5.49 % during the forecast period (2022-2029).

Imaging technologies are used in image-guided biopsy to see inside the body. By positioning the needle in the ideal location during the biopsy, the medical professional can quickly get a sample of the problematic cell. It is recognized as one of the best collection techniques because it causes little harm. This method is frequently carried out in one of the two locations, such as the Interventional Radiology (IR) suite utilizing ultrasound (sound waves) or fluoroscopy (X-rays) or the CT room using a CT scanner, as photographs are needed to guide the placement of the needle during a biopsy

Market Dynamics

Innovation in the Diagnostic Outcome of Image-Guided Percutaneous Core Needle Biopsy of Sclerotic Bone Lesions is expected to drive market growth.

The diagnostic yield of image-guided percutaneous CNB of sclerotic bone lesions has accuracy in estimating and differentiating benign from malignant lesions and shows very good results. Moreover, compared to the manual technique, the battery-powered bone biopsy device had a greater pooled fraction of the diagnostic output. For instance, numerous investigations found that sclerotic bone lesions had lower diagnostic yields than lytic bone lesions. Sclerotic lesions have substantially reduced tumor cellularity and reactive bone production. The manual drill mechanism is replaced with a battery-powered drill system to get around this restriction. This method is utilized for the aspiration and biopsy of bone marrow before being used for the biopsy of sclerotic bone lesions. The battery-powered drill device is found to have various benefits in these tests, including improved specimen size and quality and decreased process time, radiation dosage, and other factors. Therefore, considering these results, image-guided percutaneous CNB of sclerotic bone lesions is a reliable diagnostic method with a high diagnostic yield, especially when battery-powered bone biopsy equipment is employed. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

The increased concerns about the possibility of infections from aspiration and biopsy needles, the underdeveloped healthcare system, and the lack of skilled radiologists and oncologists are some factors the market is expected to get hampered in the forecast period.

Industry Analysis

The image-guided biopsy market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, reimbursement scenario, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. To preserve personal protective equipment (PPE), increase hospital capacity and safeguard patients in need of non-urgent surgery and other operations from virus infection in the hospital setting, elective medical treatments have been postponed in the United States. Scheduling templates should emphasize radiologic examination of high-risk women using mammography and MRI above screening for low-risk patients. Moreover, patients are examined for COVID-19 symptoms and tested if a disease is suspected if she requires an image-guided biopsy. If the biopsy results are positive, it is postponed as much as possible to protect staff and other patients from exposure and to prevent complicating the patient's COVID-19 condition. An image-guided biopsy can be performed if there are no symptoms or indicators of COVID-19 or if the test results in a negative result. To safeguard patients and staff, radiology facilities implemented measures comparable to those mentioned above before reintroducing screening tests and image-guided biopsies.

Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

MRI segment is expected to hold the largest market share in image-guided biopsy market

The MRI segment is expected to dominate in 2021. The segment benefits because the technique can be finished within one hour and is less invasive than surgical biopsy. It also leaves little to no scars. Radiation-free imaging is possible with MRI, a non-invasive imaging method. An MRI-guided breast biopsy is quicker, less invasive, and less expensive than a surgical biopsy. Patients can quickly resume their regular activities after recovery. Moreover, ionizing radiation is not used during MRI-guided biopsy. Using either the vacuum-assisted device or the core needle technique. Therefore, it has increased the demand for MRI image-guided biopsy. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global image-guided biopsy market

In 2021, North America accounted for the highest revenue share. The rising geriatric population, the increasing prevalence of cancer, enhanced healthcare infrastructure, increased investment, rising healthcare costs, product launches and acquisitions by the market players are some factors the market is expected to boost in the forecast period. For instance, 1,752,735 new cancer cases were reported in the United States in 2019, while 599,589 people died from the disease. Four hundred thirty-nine new cases of cancer and 146 cancer-related deaths were reported for every 100,000 persons. In contrast, in the US, 1,806,590 new cancer cases and 606,520 cancer-related deaths are anticipated in 2020, or 4,950 new cases and more than 1,600 fatalities daily. Therefore, by taking out and studying a sample of the relevant tissue or fluid, aspiration and biopsy are frequently used to investigate the nature of malignancies. Image-guided biopsy demand is rising due to government and medical organizations stepping up efforts to provide improved diagnostic services in response to the rising cancer incidence.

In addition, Cook Medical's breast localization needle and soft tissue biopsy product lines were bought by IZI Medical Products in January 2019. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the image-guided biopsy market are Koninklijke Philips N.V, Siemens Healthcare GmbH, GE Healthcare, Brainlab, Medtronic, Olympus Corporation, Stryker, Hologic Inc.

GE Healthcare:

Overview:

GE Healthcare is a subsidiary of American multinational conglomerate General Electric Company. The company manufactures and distributes diagnostic imaging agents and radiopharmaceuticals for imaging modalities used in medical imaging procedures as of 2017. Dyes for magnetic-resonance imaging methods are available from the firm. GE Healthcare also manufactures medical diagnostic equipment, including CT image machines. Moreover, it develops Health technology for medical imaging and information technologies, medical diagnostics, patient monitoring systems, disease research, drug discovery, and biopharmaceutical manufacturing. The company is operated in more than 100 countries.

¬Product Portfolio:

CT-Guided Biopsy: A biopsy method locates an abnormal body area using a CT scan, a specialized sort of x-ray connected to a computer. It uses that location to help guide the removal of a tissue sample. Typically, a needle retrieved the sample and examined for illness indicators under a microscope.

The global image-guided biopsy market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.